Insmed (NASDAQ:INSM) Research Coverage Started at HC Wainwright
HC Wainwright began coverage on shares of Insmed (NASDAQ:INSM – Free Report) in a research report sent to investors on Wednesday, Marketbeat.com reports. The brokerage issued a buy rating and a $220.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Insmed’s Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at […]
7 Nov 14:38 · The Markets Daily